Latest DEF 14A proxy statements

Fusemachines Inc. has issued its 2026 proxy statement detailing the upcoming annual meeting, including director elections and an equity incentive plan amendment.

Ovid Therapeutics Inc. has filed its definitive proxy statement for the 2026 Annual Meeting of Stockholders to be held virtually on June 10, 2026.

Alight, Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for June 10, 2026, and is proposing several amendments to its Charter, including declassifying the board, providing officer exculpation, and authorizing reverse stock splits.

LendingTree's 2026 proxy statement outlines the upcoming annual meeting, board elections, and executive compensation following the passing of founder and CEO Doug Lebda.

DigitalBridge Group, Inc. files its 2026 proxy statement ahead of its annual meeting, seeking approval for director elections, executive compensation, and an amendment to its 2024 Omnibus Stock Incentive Plan.

Ascent Solar Technologies, Inc. has issued its 2026 proxy statement detailing proposals for its upcoming annual meeting on June 17, 2026.

Metagenomi Therapeutics, Inc. has scheduled its 2026 Annual Meeting of Stockholders for June 9, 2026, to conduct routine director elections and auditor ratification.

Brilliant Earth Group, Inc. has issued its 2026 proxy statement detailing the upcoming virtual annual meeting, director elections, and auditor ratification.

Century Therapeutics has filed its 2026 proxy statement, outlining director elections, auditor ratification, and a proposal to increase authorized common stock.

Atea Pharmaceuticals announces its 2026 Annual Meeting of Stockholders, focusing on director elections, executive compensation, and clinical pipeline progress.

Quince Therapeutics announces its 2026 Annual Meeting, seeking shareholder approval for a reverse stock split to maintain Nasdaq compliance.

Bio Green Med Solution, Inc. has scheduled its 2026 Annual Meeting of Stockholders for June 18, 2026, to be held via a virtual-only format.

Alliance Laundry Holdings Inc. has issued its 2026 proxy statement detailing director elections, executive compensation advisory votes, and auditor ratification.

Nuvectis Pharma, Inc. has issued its proxy statement for the 2026 Annual Meeting of Stockholders to be held virtually on June 11, 2026.

SandRidge Energy, Inc. has issued its 2026 proxy statement detailing the upcoming annual meeting, director elections, and a proposal to extend its Omnibus Incentive Plan.

HubSpot's 2026 Proxy Statement outlines director elections, executive compensation, and a proposed amendment to the 2024 Stock Option and Incentive Plan.

Traeger, Inc. has issued its 2026 proxy statement detailing the upcoming annual meeting, director elections, and executive compensation updates.

Payoneer Global Inc. has released its 2026 Proxy Statement, detailing the upcoming Annual Meeting of Stockholders on June 9, 2026, and outlining key governance, compensation, and director election proposals.

Spero Therapeutics, Inc. has issued its 2026 proxy statement detailing proposals for director elections, executive compensation, and a significant increase in authorized common stock.

Abeona Therapeutics Inc. has issued its 2026 proxy statement detailing proposals for director elections, executive compensation, and an increase in equity incentive plan shares.

Sallie Mae's 2026 proxy statement outlines director elections, executive compensation, and strategic initiatives following a strong 2025 performance.

Gyre Therapeutics schedules its 2026 Annual Meeting for June 10, 2026, to vote on director elections, executive compensation, auditor ratification, and the conversion of Series B Preferred Stock related to the Cullgen merger.

Serina Therapeutics has scheduled its 2026 Annual Meeting for June 17, 2026, to address key capital structure, equity incentive, and governance proposals.

Butterfly Network, Inc. has issued its 2026 proxy statement detailing the upcoming annual meeting of stockholders to be held virtually on June 18, 2026.

OceanFirst Financial Corp. has released its 2026 proxy statement detailing the upcoming annual meeting, executive compensation, and the proposed 2026 Stock Incentive Plan.

Sensei Biotherapeutics seeks stockholder approval for post-acquisition governance, share authorization, and equity plans following its merger with Faeth Therapeutics.

SCYNEXIS, Inc. has scheduled a special meeting for May 19, 2026, to seek stockholder approval for a reverse stock split to regain compliance with Nasdaq minimum bid price requirements.

Krispy Kreme's 2026 proxy statement outlines board changes, executive compensation, and proposals for the upcoming annual meeting.

Target Corporation has released its 2026 Proxy Statement, detailing the agenda for its upcoming Annual Meeting of Shareholders, including director elections, executive compensation, and shareholder proposals.

Coupang, Inc. has issued its proxy statement for the 2026 Annual Meeting of Stockholders, detailing proposals for director elections, auditor ratification, and executive compensation.